Product Description
Mechanisms of Action: IL1B Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Avalo Therapeutics
Company Location: ROCKVILLE MD 20850
Company CEO: Garry Neil
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Hidradenitis Suppurativa
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|